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Abstract
Purpose PARP inhibitors (PARPi) are used in a wide range of human solid tumours but a limited evidence is reported in 
rhabdomyosarcoma (RMS), the most frequent childhood soft-tissue sarcoma. The cellular and molecular effects of Olapa-
rib, a specific PARP1/2 inhibitor, and AZD2461, a newly synthesized PARP1/2/3 inhibitor, were assessed in alveolar and 
embryonal RMS cells both as single-agent and in combination with ionizing radiation (IR).
Methods Cell viability was monitored by trypan blue exclusion dye assays. Cell cycle progression and apoptosis were 
measured by flow cytometry, and alterations of specific molecular markers were investigated by, Real Time PCR, Western 
blotting and immunofluorescence experiments. Irradiations were carried out at a dose rate of 2 Gy (190 UM/min) or 4 Gy 
(380 UM/min). Radiosensitivity was assessed by using clonogenic assays.
Results Olaparib and AZD2461 dose-dependently reduced growth of both RH30 and RD cells by arresting growth at G2/M 
phase and by modulating the expression, activation and subcellular localization of specific cell cycle regulators. Downregu-
lation of phospho-AKT levels and accumulation of γH2AX, a specific marker of DNA damage, were significantly and per-
sistently induced by Olaparib and AZD2461 exposure, this leading to apoptosis-related cell death. Both PARPi significantly 
enhanced the effects of IR by accumulating DNA damage, increasing G2 arrest and drastically reducing the clonogenic 
capacity of RMS-cotreated cells.
Conclusions This study suggests that the combined exposure to PARPi and IR might display a role in the treatment of RMS 
tumours compared with single-agent exposure, since stronger cytotoxic effects are induced, and compensatory survival 
mechanisms are prevented.
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Introduction
Rhabdomyosarcoma (RMS) is the most common childhood 
soft tissue sarcoma, representing approximately 50% of all 
sarcomas in children aged 0–14 years (McDowell 2003; 
O’Neill et al. 2013). Adolescents and more rarely adults may 
also be affected (Ferrari et al. 2003). RMS is a heterogene-
ous tumour that is believed to develop as a result of genetic 
alterations occurring in mesenchymal progenitor/stem cells, 
which express some markers of normal skeletal muscle but 
show an incompletely differentiated muscle phenotype 
(Merlino and Helman 1999). Alveolar RMS (ARMS) and 
embryonal RMS (ERMS), the two most common histologi-
cal subtypes in childhood, have distinct clinicopathological 
features and outcomes (Coffin 1997; Parham and Barr 2013). 
ARMSs and ERMSs are both characterised by distinctive 
genetic alterations that are likely to play a decisive role in 
their pathogenesis (Anderson et al. 1999; Goldstein et al. 
2006; Martinelli et al. 2009; Marshall and Grosveld 2012; 
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Parham and Barr 2013; Robbins et al. 2016). ERMSs are 
more frequent (~ 80% of cases) and generally affect younger 
children (0–4 years), occurring more commonly in the neck, 
head and genito-urinary tract (Parham and Barr 2013). 
ARMSs (~ 20% of cases) usually present throughout child-
hood and adolescence, frequently originate in the extremi-
ties and trunk, often with regional or metastatic lymph node 
involvement already at diagnosis, and have high tendency 
to metastasize carrying a significantly worse outcome (Par-
ham and Barr 2013). Indeed, 70% of children with localized 
disease survive with conventional treatment (Arndt et al. 
2009), including surgery, radiotherapy and chemotherapy. 
Metastatic RMSs, however, are frequently resistant or pre-
sent relapse after an initial response, with a 5-year event-free 
survival rate at about 30% (Sorensen et al. 2002; Ognjanovic 
et al. 2009; Wolden et al. 2015). Therefore, the outcome for 
high-risk RMS cases remains very poor and the discovery 
of innovative therapies is an absolute priority to improve 
therapeutic activity and reduce toxicity.
Poly(ADP-ribose) polymerases (PARPs) belong to a large 
family of enzymes that catalyse the formation of poly(ADP-
ribose) polymers (PARylation) onto different targets and 
themselves, this leading to a fine modulation of different 
cellular processes and molecular pathways, such as DNA 
damage response (DDR), cellular differentiation, chromatin 
remodelling, transcription, cell death and mitotic progres-
sion (Helleday et al. 2007; Dungey et al. 2008; De Vos et al. 
2012; Bai 2015; Brown et al. 2017). Only PARP1 and, to a 
lesser extent, PARP2 and PARP3 play an essential role in 
repairing single- or double-stranded DNA breaks (SSBs or 
DSBs, respectively) as well as stalled replication forks and 
DNA crosslinks (De Vos et al. 2012), with PARP2 being 
specifically able to recognize DNA gaps and flaps (Yélamos 
et al. 2008) and PARP3 being selectively activated by DSBs 
(Boehler et al. 2011). PARP1 and PARP2 are involved in 
fixing DNA-strand interruptions by the homologous recom-
bination (HR) pathway (Henning and Stürzbecher 2003), 
whilst PARP3 acts via the nonhomologous end joining 
(NHEJ) repair system (Davis and Chen 2013).
PARP inhibitors (PARPi) comprehend a wide range of 
chemical compounds able to abrogate PARP functionality 
thus bringing to the accumulation of SSBs, which in turn are 
converted into DSBs that cells are not able to repair causing 
cancer cell death (Wiltshire et al. 2010). The mechanism of 
action of PARPi is the block of the catalytic domain of PARP 
enzymes, but these agents can also trap PARP proteins on the 
double-stranded DNA helix, this leading to cytotoxic lesions 
(Murai et al. 2012; D’Arcangelo et al. 2016). PARP inhibition 
has a potential therapeutic role as monotherapy in tumours 
carrying constitutive mutations in DDR genes, as well as in 
combination therapies for its ability to enhance the activity 
of anticancer drugs with genotoxic action, including DNA 
alkylating agents, topoisomerase II inhibitors and ionising 
radiation (IR) (Jorgensen 2009; Kelley et al. 2014; Lord and 
Ashworth 2017), since targeting similar molecular functions 
results in cell death. The “synthetic lethality” conferred by 
PARPi (Martin et al. 2008; Lord and Ashworth 2017) is not 
only restricted to BRCA1- and BRCA2-mutated tumours but 
also to neoplasia harbouring genetic alterations in other HR 
genes, such as ATM, RAD51, PTEN, XRCC2, etc (Bang 
et al. 2013; Kelley et al. 2014), this suggesting a therapeutic 
potential role of PARP inhibition in a wide range of human 
malignancies. Several clinical trials aimed at assessing for dif-
ferent PARPi are in progress. Olaparib (AZD2281), a selective 
inhibitor of PARP1 and PARP2, has been used in different 
solid tumours and, recently, this drug has been approved as 
personalized therapy (Kim et al. 2015; Goulooze et al. 2016) 
for patients with BRCA1/2-mutated advanced ovarian cancer, 
who have been treated with three or more prior lines of chemo-
therapy (Phase III clinical trial, NCT01874353). AZD2461, a 
next-generation agent able to also inhibit PARP3 activity, has 
been recently synthesised in order to overcome PARPi-related 
resistance and to be better tolerated than Olaparib (Jaspers 
et al. 2013; O’Connor et al. 2016; Vaidyanathan et al. 2016). 
An encouraging therapeutic activity has recently been reported 
in clinical trials with AZD2461 on refractory solid tumours 
(Phase I clinical trial, NCT01247168).
A limited amount of information is available about the 
effects and the molecular mechanisms of PARP inhibition, 
as monotherapy or in combination with conventional thera-
pies, in RMS. Only very recently, Mangoni et al. have shown 
that pretreatment with Olaparib, Iniparib or Veliparib, three 
PARP1 inhibitors, is able to induce a significant radiosensi-
tization in different soft tissue sarcoma cell lines (Mangoni 
et al. 2018).
In the present study, we analysed the expression of 
PARP1, PARP2 and PARP3 genes in a panel of RMS pri-
mary tumours and cell lines, and evaluated the biological 
and molecular effects of PARP inhibition in RMS in vitro 
models by using Olaparib or AZD2461. We tested two dif-
ferent doses of both PARPi and determined the minimum 
concentrations of each molecule able to drive a biologi-
cal effect in RH30 and RD cell lines, two in vitro models 
of ARMS and ERMS, respectively. We also assessed the 
possible synergistic effects between Olaparib or AZD2461 
and IR, a combination which might represent a further step 
towards a more effective treatment of RMS patients, espe-
cially those with metastatic disease.
Methods
Reagents and irradiation
Olaparib and AZD2461 were purchased from Selleckchem 
(Suffolk, UK) and were reconstituted at 10 mM using 
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dimethyl sulfoxide (DMSO). DMSO alone was used as 
control in untreated cells at 0.1% (v/v) concentration.
Irradiation was carried out using an ONCOR Impres-
sion Linear Accelerator (Siemens Medical Solutions USA, 
Inc, Concord, CA) at a dose rate of 2 Gy (190 UM/min) or 
4 Gy (380 UM/min).
Cell cultures
Human RMS cell lines, RH30 (alveolar) and RD (embryo-
nal), were maintained as previously described (Megiorni 
et al. 2016). Human foetal myoblast (HFM) cells were 
cultured in High Glucose DMEM supplemented with 20% 
FBS.
Tumour samples
Seventeen RMS tumour samples, 4 ARMSs and 13 ERMSs, 
were obtained at diagnosis before any treatment from chil-
dren admitted to the Department of Oncology at Alder Hey 
Children’s NHS Trust, Liverpool. ARMS1-2-4 are fusion-
positive tumours, whilst ARMS3 is a fusion-negative case, 
as assessed by FISH analysis for PAX3/7-FOXO1 transloca-
tions. Institutional written informed consent was obtained 
from the patient’s parents or legal guardians. The study 
underwent ethical review and approval according to the 
local institutional guidelines (Alder Hey Children’s NHS 
Foundation Trust Ethics Committee, approval number 09/
H1002/88).
RNA extraction and quantitative Real Time PCR 
(q‑PCR)
Total RNA, isolated from RMS tumour biopsies and cell 
lines, was reverse transcribed and analysed by using quanti-
tative Real Time PCR (q-PCR) with specific TaqMan Real-
Time Gene Expression Assays (Applied Biosystems), as 
previously described (Megiorni et al. 2016). Human PARP1 
(Hs00242302_m1), PARP2 (Hs00193931_m1) and PARP3 
(Hs00193946_m1) mRNA assays were used. Samples were 
normalized according to GAPDH transcript levels. Expres-
sion of miR-124-3p was analysed as previously described 
(Megiorni et al. 2014), by using sequence-specific TaqMan 
MicroRNA Assays (Applied Biosystems). U6 small nuclear 
RNA levels were used as internal control. The amount of 
each mRNA or miRNA was calculated by the comparative 
Ct method (Livak and Schmittgen 2001) and expressed as 
fold change using the StepOne v2.3 software (Applied Bio-
systems). Each sample was run in triplicate, in at least two 
independent experiments.
Cell proliferation assays
RH30 and RD cells (3 × 105) were plated in six-well plates 
and treated with Olaparib (1.5 and 5 µM) or AZD2461 (5 
and 10 µM). After 72 h, RH30 and RD living cells were 
diluted in a 1:1 mixture of trypan blue (Invitrogen) and 
counted using the Countess II Automated Cell Counter 
(Invitrogen), according to the manufacturer’s instructions.
Morphological assessment
RH30 and RD cells treated with Olaparib (1.5 and 5 µM) or 
AZD2461 (5 and 10 µM) for 72 h were photographed with 
an Axio Vert.A1 microscope (Carl Zeiss Microscopy, Thorn-
wood, NY), furnished with an AxioCam MRc5 camera (Carl 
Zeiss Microscopy), at 20× magnification.
Cell cycle and apoptosis analysis by flow cytometry
For the cell cycle analysis, RH30 and RD cells (3 × 105) 
were incubated in six-well cell culture plates overnight to 
allow cell adhesion. Cells were treated with Olaparib (1.5 
and 5 µM) or AZD2461 (5 and 10 µM) for 48 h. DMSO was 
used as mocked control. For the cell cycle analysis of the 
effects induced by the PARPi and IR combination, RH30 
and RD cells, pretreated for 24 h with Olaparib or AZD2461 
were irradiated and incubated for additional 24 h at 37 °C. 
Samples were stained with Propidium Iodide (PI) solution 
and subjected to flow cytometry by using a BD FACSCali-
bur (BD Biosciences, Franklin Lakes, NJ), as previously 
described (Megiorni et al. 2016). FACS data were quanti-
fied by using the ModFit LT 3.0 program (Verity Software 
House). Experiments were performed at least twice.
Apoptosis was analysed by using PE Annexin V Apopto-
sis Detection Kit I (BD Biosciences), following the manu-
facturer’s instructions. Briefly, RH30 and RD cells (3 × 105) 
were seeded overnight in six-well plate and treated with 
Olaparib, AZD2461 or DMSO for 48 and 144 h. Approxi-
mately 2 × 105 cells were stained with Annexin V and 
7-Amino-Actinomycin (7-AAD) for 15 min at RT in the 
dark. Fluorescence intensities of treated samples and con-
trols were analysed by flow cytometry by using the BD Cell-
Quest Pro software. Experiments were performed at least 
twice.
Colony formation assay
RH30 and RD cells (3.2 × 105) treated for 24 h with Olaparib 
(1.5 and 5 µM) or AZD2461 (5 and 10 µM), were irradiated 
at a dose of 2 or 4 Gy/min. After 4 h incubation at 37 °C, 5% 
 CO2, 2 × 103 cells/well were seeded in 6-well plates in tripli-
cate. Medium was replaced every 3 days and after 12 days, 
colonies were stained with 0.1% crystal violet for 5 min 
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at room temperature (RT). Colonies were photographed, 
and then crystal violet was solubilised in 30% acetic acid 
in water for 15 min at RT; absorbance was measured by 
using the Biochrom Libra S22 UV/VIS spectrophotometer 
(Biochrom, Berlin, DE) at wavelength of 595 nm; 30% ace-
tic acid in water was used as the blank. Colony formation 
capacity in PARPi- and/or IR-treated cells was calculated 
in comparison to mocked control samples (DMSO alone), 
arbitrarily set to 1. The results were plotted as means ± SD 
of two separate experiments having three determinations per 
assay for each experimental condition.
Protein extraction and Western blotting
Total protein extracts and Western blotting assays were per-
formed as previously described (Megiorni et al. 2016) using 
the following primary antibodies: phospho (p)-AKT, AKT, 
cleaved caspase 3, and γH2AX (Cell Signalling Technology, 
Danvers, MA); Bcl2, Cdc2 phosphorylated at Thr14/Tyr15, 
Cdc25C, Cyclin B1, Cyclin D1 and p21 (Santa Cruz Bio-
technology, Dallas, TX). Antibody against tubulin (Sigma-
Aldrich) was used as a loading control.
Immunofluorescence (IF) microscopy
RH30 and RD cells (5 × 104), seeded onto 2% gelatine 
coated-glass coverslips in 24-well plates, were allowed to 
attach overnight and then incubated for 48 h in the pres-
ence or absence of Olaparib (5 µM) or AZD2461 (10 µM). 
For IF analysis of the effects induced by the PARPi and IR 
combination, RH30 and RD cells, pretreated for 24 h with 
Olaparib or AZD2461 were irradiated and incubated for 
additional 4 h at 37 °C. IF assays were performed as previ-
ously described (Megiorni et al. 2016) using the following 
primary antibodies: Cdc2, p-Cdc2, Cdc25C, Cyclin B1, Cyc-
lin D1, RAD51 (1:20 dilution in PBS; Santa Cruz Biotech-
nology), and γH2AX (1:500 in PBS; Cell Signaling). All 
single-stained or merged images were acquired with a Zeiss 
ApoTome microscope (40× magnification) using the Axiovi-
sion software (Carl Zeiss, Jena, Germany). For γH2AX and 
RAD51, focus fluorescence intensity in the respect of cell 
number in each analysed field was reported.
Statistical analysis
Data are presented as means ± SD. Statistical analyses were 
performed by two-tailed Student’s t test and a probability 
(p) < 0.05 was considered statistically significant. All the 
experiments were done in triplicates and repeated three 
times unless mentioned otherwise.
Results
PARP1, PARP2 and PARP3 are upregulated in ARMS 
and ERMS tumours and cell lines
Transcript levels of PARP1, PARP2 and PARP3 genes 
were evaluated in a panel of 17 RMS primary tumours 
(4 ARMSs and 13 ERMSs) by quantitative Real Time 
PCR (q-PCR) experiments. PARP1, PARP2 and PARP3 
(Fig. 1a) mRNAs are all significantly overexpressed in 
RMS biopsies compared with normal skeletal muscle 
(NSM), with a 9.3-, 7.1- and 4.2-fold average increase in 
PARP1, PARP2 and PARP3 expression, respectively.
PARP expression was also analysed in two ARMS (RH4 
and RH30) and three ERMS (RD, RD18 and TE671) cell 
lines, and higher levels of PARP1, PARP2 and PARP3 
transcripts were demonstrated in comparison to proliferat-
ing myoblasts (HFMs), with the only exception of PARP3 
in RH4 cell line (Fig. 1b). Aberrant expression of PARPs 
in RMS suggests that these genes might be further inves-
tigated as potential therapeutic targets in RMS tumours.
Olaparib and AZD2461 inhibit cell proliferation 
in RMS cell lines by inducing cell cycle arrest in G2/M 
phase
The effects of Olaparib, able to block both PARP1 and 
PARP2 activity (Goulooze et al. 2016), and AZD2461, 
a newly synthesised PARP1/2/3 inhibitor (Boehler et al. 
2011), were evaluated in RMS cell lines. Increasing con-
centration of Olaparib (1.5 and 5 µM) or AZD2461 (5 
and 10 µM) clearly affected the morphologic appearance 
of both RH30 and RD cells, as confirmed by microscope 
acquisitions at 48 h, with cells becoming dose-depend-
ently larger in comparison to the control cells (Fig. 2a). 
Furthermore, PARPi-treated cells showed a significant 
dose-dependent reduction in their number (Fig.  2b): 
direct counting for living cells using the trypan blue dye 
exclusion test showed that Olaparib exposure is able to 
inhibit cell growth by about 35% at 1.5 µM in both RMS 
cell lines, whilst higher concentrations (5 µM) reduced 
proliferation by 70% in RH30 cells and by 60% in RD 
compared to the untreated samples (Fig. 2b); AZD2461 
led to about 35% decreased cell growth at 5 µM and to 
60% at 10 µM in both RMS cell lines compared to mocked 
controls (Fig. 2b).
In order to determine whether the Olaparib- and 
AZD2461-dependent decreases in RMS cell growth were 
due to alterations in cell cycle progression, flow cytometry 
analysis was performed in RH30 and RD cells. Based on 
PI staining of cellular DNA content, cells significantly 
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arrested in G2 phase (4n) when treated for 48  h with 
Olaparib or AZD2461 with a corresponding decrease 
of cell percentage in both G1 (2n) and S phases, whilst 
untreated cells rapidly divided and progressed through 
the cell cycle at high rates (Fig. 2c). Indeed, a maximum 
4n-peak was observed at the higher drug concentrations 
(from 6.7 ± 1.7% in DMSO to 77.4 ± 2.8% in 5 µM Olapa-
rib and 73.6 ± 2.5% in 10 µM AZD2461 RH30 cells; from 
12.0 ± 2.7% in DMSO to 63.5 ± 2.4% in 5 µM Olaparib and 
65.6 ± 2.1% in 10 µM AZD2461 RD cells), confirming a 
dose-dependent accumulation of cells in the G2/M phase 
in both RMS cell lines (Fig. 2c).
To analyse the mechanisms underlying these cell cycle 
perturbations, the impact of Olaparib and AZD2461 on the 
expression and activation status of proteins related to cell 
cycle checkpoints was investigated. Western blotting exper-
iments showed that the PARPi-mediated G2/M cell cycle 
arrest was associated with a dose-dependent upregulation 
of Cyclin B1, phospho (p)-Cdc2, Cdc25C and p21 proteins, 
as well as with a concomitant downregulation of Cyclin D1 
levels in both RH30 and RD cells (Fig. 2d). IF experiments 
showed alterations in the expression, activation and sub-
localization of cell cycle regulators in the RMS cell lines, 
especially at the maximum Olaparib (5 µM) or AZD2461 
(10 µM) used dosages (Fig. 3a, b). Olaparib and AZD2461 
single exposure for 48 h caused a cytoplasmatic retention 
of Cdc25C, a protein involved in the mitosis entry, in both 
RH30 and RD treated-cells (Fig. 3a, b). The marked up-
regulation of Cdc2 phosphorylation levels at Thr14/Tyr15 in 
both cell lines treated with Olaparib or AZD2461 confirmed 
that the Cdc2 protein was in its inactive form (Fig. 3a, b). 
Cyclin D1 cytoplasmatic levels also resulted downregulated 
in PARPi-treated RH30 (Fig. 3a) and RD cells (Fig. 3b). 
Furthermore, Cdc2 and Cyclin B1, two G2/M-regulating 
proteins, co-localized outside the nuclear portion with a 
massive staining evident in the perinuclear area (Fig. 3a, 
b) in both PARPi-treated RMS cells. This finding suggests 
that the complex Cdc2/Cyclin B1 was no longer able to enter 
the nucleus, this leading to the G2/M arrest evidenced by 
FACS analysis.
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Fig. 1  PARP1, PARP2 and PARP3 expression in RMS tumours and 
cell lines. a Quantitative real time PCR (q-PCR) analysis of PARP1, 
PARP2 and PARP3 mRNA levels in 17 RMS primary tumours (4 
ARMSs and 13 ERMSs), expressed as fold increase over normal 
skeletal muscle (NSM), arbitrarily set at 1. Transcript levels were 
normalized to GAPDH mRNA and error bars represent SD of two 
independent q-PCR reactions, each performed in triplicate. b q-PCR 
of PARP1, PARP2 and PARP3 mRNA levels in ARMS (RH4 and 
RH30) and ERMS (RD, RD18 and TE671) cell lines, expressed as 
fold increase over HFM (human foetal myoblast), arbitrarily set at 1. 
GAPDH was used as control. Bars represent mean values of two inde-
pendent experiments, each performed in triplicate
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Fig. 2  PARPi exposure affects 
cell viability and induces G2/M 
cell cycle arrest in RMS cell 
lines. a Olaparib or AZD2461 
treatment for 48 h clearly 
affected the morphology of both 
RH30 and RD cells, analysed 
under light microscope at ×20 
magnification. b Viability of 
RH30 and RD cells treated for 
48 h with increasing concentra-
tion of Olaparib or AZD2461 
expressed in relationship with 
mocked controls (DMSO), 
arbitrarily set at 100%, assessed 
by trypan blue exclusion stain-
ing. Each bar represents the 
mean value of three independ-
ent experiments ± SD. Statistical 
significance: *, p < 0.05, ***, 
p < 0.005, ns not significant 
vs. DMSO mocked controls. c 
Flow cytometry data showing 
percentages of cells in G1, S 
and G2 phases in RH30 and 
RD cells treated for 48 h with 
Olaparib (1.5 and 5 µM) or 
AZD2461 (5 and 10 µM). Data 
are average values of three inde-
pendent experiments. Statistical 
significance was < 0.005 in both 
PARPi-treated RH30 and RD 
cells vs. mocked controls. d 
Western blot analyses of a panel 
of cell cycle regulatory proteins 
(Cyclin B1, Cyclin D1, p-Cdc2, 
Cdc25C and p21) in RH30 and 
RD cells at 48 h after exposure 
to PARPi. Tubulin expression 
was used as internal control. 
Representative blots of three 
independent experiments
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Altogether, these observations demonstrate that Olaparib 
and AZD2461 display a rapid cytostatic effect in RMS cells, 
with an evident block of the cell cycle at G2/M phase.
Prolonged treatment with Olaparib and AZD2461 
induces apoptosis in RMS cell lines due to persistent 
DNA damage
To assess whether the decreased cell growth of RMS cells 
treated with PARPi was also caused by the induction of pro-
grammed cell death, flow cytometry assays with Annexin 
V-PE/7-AAD staining were performed. Treatment of RH30 
and RD cell lines with Olaparib (1.5 and 5 µM) or AZD2461 
(5 and 10 µM) for 48 h did not increase the percentage of 
cells undergoing early or late apoptosis when compared to 
mock-treated control cells (data not shown). Olaparib or 
AZD2461 significantly increased the number of apoptotic 
RH30 and RD cells only after 144 h of treatment (Fig. 4a). 
Indeed, Annexin V-PE/7-AAD double staining confirmed 
that cytotoxic effects were most pronounced after more pro-
longed exposure times at higher drug concentration, with 
an increased percentage of apoptosis in both PARPi-treated 
RMS cell lines compared with controls (Fig. 4a). Cell death 
induced by long-lasting PARPi exposure was evident in 
the morphologic appearance of both RH30 and RD cells, 
which exhibited a wide number of vacuoles and cyto-
plasm destruction, whilst DMSO-treated RMS cells rapidly 
reached confluence and grew in multiple layers (Fig. 4b). 
Furthermore, Western blot analysis showed that Bcl2 levels 
clearly decreased in RH30 and RD cells at the higher drug 
a
b
Fig. 3  Changes in molecular regulators of cell cycle in RMS cells 
treated with Olaparib or AZD2461. a Immunofluorescence experi-
ments showing the expression and localization of Cdc25C, p-Cdc2 
(Thr14/Tyr15), Cyclin D1, Cyclin B1 and Cdc2 proteins in RH30 
cells treated with 5 µM Olaparib or 10 µM AZD2461 for 48 h. Con-
trol cells were treated with DMSO. DAPI was used for nuclear stain-
ing. Images captured under ApoTome microscope at ×40 magnifica-
tion. b Immunofluorescence experiments showing the expression 
and localization of Cdc25C, p-Cdc2, Cyclin D1, Cyclin B1 and Cdc2 
proteins in RD cells treated with 5 µM Olaparib or 10 µM AZD2461 
for 48 h. Control cells were treated with DMSO. DAPI was used for 
nuclear staining. Images captured under ApoTome microscope at 
×40 magnification
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Fig. 4  Effects of Olaparib and AZD2461 treatment on apoptosis in 
RMS cell lines. a Histograms show the rate of apoptosis in RMS cells 
144 h after PAPRi treatment (1.5 and 5 µM Olaparib or 5 and 10 µM 
AZD2461). Cells were stained with Annexin V and 7-AAD and then 
analysed by flow cytometry. Data are expressed as a percentage of 
total cell number. b Images showing morphological changes observed 
in both RH30 and RD cells analysed under light microscope at 20x 
magnification at 144 h after 5 µM Olaparib or 10 µM AZD2461 treat-
ment. Unlike mocked controls, RMS treated-cells exhibited a wide 
number of vacuoles and cytoplasm destruction. c Western blots show-
ing the expression of the apoptosis related proteins, Bcl2, cleaved 
caspase-3, p-AKT (Ser473) and AKT in RH30 and RD cells after 
prolonged treatment with Olaparib or AZD2461. Tubulin expression 
was used as internal control. Representative blots of three independ-
ent experiments. d Expression levels of phospho-H2AX (γH2AX) 
analysed by western blotting experiments in RH30 and RD cells 
treated with Olaparib (1.5 and 5 µM) or AZD2461 (5 and 10 µM) for 
144 h compared to mocked control cells (DMSO). Tubulin expression 
was used as loading control. Representative blots of two independ-
ent experiments. e q-PCR analysis of miR-124-3p mRNA levels in 
RH30 and RD cells treated with increasing concentration of Olaparib 
or AZD2461 for 144 h. The results are expressed as fold increase over 
relative mocked controls (DMSO), arbitrarily set at 1. Transcript lev-
els were normalized to U6 mRNA and error bars represent SD of two 
independent q-PCR reactions, each performed in triplicate. Statistical 
significance: *, p < 0.05, **, p < 0.01, ***, p < 0.005, ns not signifi-
cant vs. DMSO mocked controls
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concentrations (Fig. 4c), whilst caspase-3 cleavage/activa-
tion proportionally increased with PARPi concentrations 
and became strongly evident at 5 µM Olaparib and 10 µM 
AZD2461 in both RMS cell lines (Fig. 4c), in accordance 
with the apoptosis data obtained by FACS analysis. Since 
AKT molecular pathway is a pivotal signal in RMS apopto-
sis (Kilic-Eren et al. 2013), activation of AKT phosphoryla-
tion at Ser473 was analysed. As observed in Western blot-
ting assays, phosphorylation levels of AKT protein (p-AKT) 
were markedly reduced in a dose-dependent way in both 
RH30 and RD cells treated with PARPi compared to the 
untreated controls, whilst AKT total levels were unchanged 
(Fig. 4c). Indeed, the treatment of RMS cells with LY29004, 
a synthetic molecule known to inhibit the PI3K/AKT axis, 
led to the downregulation of p-AKT expression and the con-
comitant upregulation of cleaved caspase 3 (data not shown), 
this confirming the central role of the AKT signal transduc-
tion pathway in the PARPi-mediated cell survival and death.
To assess if the activation of the cell death pathways was 
due to a permanent DNA damage, the accumulation of acti-
vated H2AX histone (γH2AX), a well-established marker 
for DSBs (Kuo and Yang 2008; Bonner et al. 2008), was 
evaluated in RH30 and RD cells treated with Olaparib (1.5 
and 5 µM) or AZD2461 (5 and 10 µM). Western blotting 
assays demonstrated that the γH2AX levels remain signifi-
cantly elevated in RH30 and RD treated-cells in compari-
son to mocked controls at 144 h (Fig. 4d), this suggesting 
that the persistence of DNA injury is the primary cause of 
the cellular lethality observed after prolonged exposure to 
PARPi. Since the downregulation of BCL2, the increased 
caspase 3 activation and the accumulation of γH2AX have 
been recently correlated to apoptosis by the upregulation of 
miR-124-3p (Zhang et al. 2017), we evaluated the expres-
sion of this miRNA in PARPi-treated cells. Indeed, miR-
124-3p levels significantly and dose-dependently increased 
after Olaparib (1.5 and 5 µM) or AZD2461 (5 and 10 µM) 
exposure (Fig. 4e). These results suggest that the increased 
cell death triggered by PARPi, especially at higher doses, is 
related to different molecular components, comprehending 
miRNA modulation.
Olaparib or AZD2461 in combination with IR reduces 
clonogenic capacity and increases DNA damage 
in RMS cell lines
Genotoxic damage, i.e., the formation of SSBs and DBSs in 
DNA molecules, is the most relevant mechanism by which 
IR causes cell-cycle arrest and cellular lethality (Vignard 
et al. 2013). To investigate the radiosensitising properties 
of Olaparib and AZD2461 in RH30 and RD cells, clono-
genic survival assays were performed at 12 days after drug 
treatment with or without IR. The simultaneous treatment of 
either Olaparib (1.5 and 5 µM) or AZD2461 (5 and 10 µM) 
with IR (4 Gy) was more effective than the single exposure 
to each specific PARPi agent or to irradiation, this resulting 
in a significant reduction in colony formation capacity in 
both RH30 and RD cells (Fig. 5a, b), as assessed by crystal 
violet absorbance. Indeed, PARPi/IR combination led to a 
significant decrease (≥ 85%) in colony formation and the 
effect was more evident at the lower concentration of both 
Olaparib (1.5 µM) or AZD2461 (5 µM) (Fig. 5a, b). Cell 
cycle analysis, performed 24 h after IR in the presence or 
absence of Olaparib (1.5 and 5 µM) or AZD2461 (5 and 
10 µM) pre-treatment, showed a significantly higher accu-
mulation of cells in G2 phase after the combined exposure 
compared to only irradiated (4 Gy) cells or to cells treated 
with each drug concentration but not irradiated (Fig. 6a). In 
particular, the synergistic mechanism of action was clearly 
evident at the lowest doses of both PARPi agents: in RH30 
cells (Fig. 6a upper graph), the combined exposure of 1.5 µM 
Olaparib/4 Gy led to a 2.3- and 4.4-fold increase of G2 cell 
percentage in comparison to 1.5 µM Olaparib (p = 0.013) 
and IR (p = 0.003) alone, respectively; a significant increase 
of G2 phase was observed in 5 µM AZD2461/4 Gy co-treat-
ment in comparison to 5 µM AZD2461 (1.8-fold, p = 0.017) 
or radiation alone (5.0-fold, p = 0.003). In RD cells (Fig. 7a 
lower graph), 1.5 µM Olaparib/4 Gy combined adminis-
tration resulted in a 2.3- and 2.4-fold increase of cell per-
centage at the G2 phase in comparison to 1.5 µM Olaparib 
(p = 0.023) and IR (p = 0.006) alone, respectively; a similar 
trend was obtained with 5 µM AZD2461/4 Gy compared 
to 5 µM AZD2461 (2.1-fold, p = 0.003) or IR alone (2.5-
fold, p = 0.0023). Upregulation of Cyclin B1 also closely 
matched with the PARPi/IR-induced G2 cell cycle arrest in 
both RH30 and RD cell lines (Fig. 6b), this confirming that 
the cumulative effects were more notable by using 1.5 µM 
Olaparib or 5 µM AZD2461 in combination with 4 Gy 
exposure.
In order to assess whether Olaparib and AZD2461 
exposure may sensitize RMS cells to IR by inducing DNA 
damage and impairing the DNA repair system, the abun-
dance of γH2AX and RAD51, one important component 
of the HR machinery, was analysed. The IF experiments 
confirmed that PARPi treatment combined with IR for 4 h 
induces a greater number of γH2AX and RAD51 foci in 
both RH30 and RD nuclei than either PARPi or 4 Gy sin-
gle exposure, especially at the maximum Olaparib (5 µM) 
or AZD2461 (10 µM) used dosages (Fig. 7a, b). Quantita-
tion of γH2AX and RAD51 foci in response to the differ-
ent drug and/or IR exposures is reported in Supplementary 
File 1. Western blots on RH30 and RD cell lysates, pro-
cessed 24 h after a single dose of 4 Gy in the presence or 
in absence of Olaparib (1.5 and 5 µM) or AZD246 (5 and 
10 µM), confirmed that DNA damage significantly per-
sisted at later times post IR or PARPi treatments compared 
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with control cells, with the most elevated levels of γH2AX 
being present in the cotreated samples (Fig. 7c).
Interestingly, a drastic alteration in the cell cycle dis-
tribution and anti-clonogenic effects were also observed 
when Olaparib or AZD2461 treatment was coupled with 
IR at 2 Gy, this suggesting that an effective anti-tumour 
activity in RMS cells is already achieved at a lower dos-
age of the different therapeutic modalities (Supplementary 
File 2).
Altogether, these results demonstrate that Olaparib and 
AZD2461 may sensitize RMS tumour cells to the irradiation.
Discussion
RMS is the most frequent soft tissue sarcoma in childhood 
(McDowell 2003; O’Neill et al. 2013). Even if the survival 
probability has increased to about 70% for children and 
adolescents with RMS (Ognjanovic et al. 2009), the 5-year 
survival rate for patients with relapsed or metastatic disease 
is approximately 40%, mainly due to the development of 
chemo- and radioresistances (Wolden et al. 2015). Therefore, 
novel more effective therapeutic strategies are a pressing 
need, in those advanced patients.
In the present study, RH30 and RD cell lines—two in vitro 
models of ARMS and ERMS subtypes, respectively—were 
used to evaluate the cellular and molecular responses to the 
PARP inhibitors Olaparib and AZD2461, as single agents or 
in combination with IR. PARPi have strong cytotoxic effects 
in tumours harbouring genetic mutations in the components 
of the DDR system, such as BRCA1, BRCA2, PTEN and 
XCCR4, due to a mechanism indicated as “synthetic lethal-
ity”, according to which the inability to correct PARPi-
induced SSBs leads to fatal DNA damage and cellular death 
(Brown et al. 2017). This study showed that the treatment 
with Olaparib, a specific inhibitor of PARP1 and PARP2 
enzymes, or AZD2461, a newly PARP1/2/3 competitor, used 
as single agents, reduces cell proliferation in both RH30 and 
RD cells in a dose dependent manner, with a marked arrest 
in the G2/M phase of the cell cycle. In accordance with the 
flow-cytometry data, Olaparib or AZD2461-treated cells 
showed morphological alterations, such as an evident cell 
volume enlargement, which are characteristic of a defec-
tive cell division arrest (Fig. 2a). These observations are 
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Fig. 5  PARPi single exposure radiosensitizes RH30 and RD cells, 
and decreases clonogenic ability of RMS cells. RH30 and RD cells 
untreated (DMSO) or pretreated with Olaparib or AZD2461 for 24 h 
were irradiated or not with a single dose of 4  Gy. Four h after IR, 
cells were seeded at low concentration and allowed to grow for 12 
days to examine their colony formation capacity. Representative pic-
tures of RH30 (a) and RD (b) colonies stained with crystal violet. 
Colony forming efficiency was calculated by crystal violet absorb-
ance from two independent experiments, each performed in tripli-
cate. Each bar represents the means ± SD. Statistical significance: **, 
p < 0.01, ***, p < 0.005, ns not significant vs. DMSO mocked con-
trols
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in agreement with data very recently reported by Mangoni 
et al. (2018). In the present study we examined in detail 
the molecular mechanisms of PARPi effects on cell cycle 
progression and survival. We showed that changes in cell 
cycle distribution are driven by the deregulation of specific 
regulatory markers: (1) PARPi treatment led to the down-
regulation of Cyclin D1 expression and to the overexpres-
sion of p21 cell cycle regulator; and (2), PARPi activated 
the G2/M checkpoint in RMS cells by sequestering Cdc25C 
in the cytoplasm compartment, promoting hyper-phospho-
rylation of Cdc2 (p-Cdc2) at Thr14/Tyr15, and upregulating 
Cyclin B1 levels. Specifically, Cyclin B1 protein resulted 
predominantly accumulated around the nuclear envelope, 
this confirming that high levels of p-Cdc2 are not able to 
form an active complex with Cyclin B1, a phenomenon that 
prevents their entrance in the nucleus and stalls the mitosis 
process as reported in other cancer types (Jin et al. 1996). 
Concerning cell survival, PARPi prolonged exposure led 
to apoptosis through the inhibition of AKT activation and 
the modulation of relative downstream molecules. Indeed, 
reduced levels of phospho-AKT and Bcl2 proteins, with the 
concomitant cleavage and activation of the caspase-3 pro-
tein were observed in PARPi-treated cells. The present find-
ings also demonstrate that the cell survival impairment we 
observed is linked to the accumulation of the DNA damage, 
which PARPi-treated cells are unable to repair. Phospho-
rylation of histone H2AX on serine 139 to form γH2AX, 
a sensitive marker for the indirect quantification of DNA 
DSBs (Bonner et al. 2008), was not only evident after 48 h 
of drug exposure but was significantly increased after 144 h 
in both Olaparib and AZD2461-treated cells, this explaining 
the observed severe consequences on the RMS cell survival. 
Indeed, persistence of γH2AX signal (Löbrich et al. 2010) 
correlated with an inefficient reconstitution of the DNA 
integrity, which is essentially performed by the HR signal-
ling molecules in the G2/M phase (Polo and Jackson 2011). 
Fig. 6  Olaparib and AZD2461 
treatment in combination with 
IR induces a strong increase 
of RMS cells in G2/M phase. 
RH30 and RD cells untreated 
(DMSO) or pretreated with 
Olaparib (1.5 and 5 µM) or 
AZD2461 (5 and 10 µM) for 
24 h were irradiated or not with 
a single dose of 4 Gy. Cells 
were incubated for additional 
24 h at 37 °C. a Flow cytometry 
data showing percentages of 
RH30 and RD cells in G1, S 
and G2 phases. Data are aver-
age values of two independent 
experiments. b Western blot 
analyses of cell cycle regulatory 
protein Cyclin B1 in RH30 and 
RD cells 48 h after exposure 
to PARPi and 24 h after IR. 
Tubulin expression was used as 
the internal control. Representa-
tive blots of two independent 
experiments
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Fig. 7  Exposure to Olaparib 
and AZD2461 increases DNA 
damage after radiation treat-
ment in RMS cell lines. a RH30 
cells, untreated (DMSO) or 
pretreated with 5 µM Olaparib 
or 10 µM AZD2461 for 24 h, 
were irradiated or not with a 
single dose of 4 Gy. Four h after 
IR, cells were fixed for immu-
nofluorescence experiments. 
Expression and localization of 
γH2AX and RAD51 proteins 
were analysed. DAPI was used 
for nuclear staining. Images 
captured under ApoTome 
microscope at ×40 magnifica-
tion. The square in each panel 
represents a magnification of 
γH2AX and RAD51 foci. b 
RD cells, untreated (DMSO) or 
pretreated with 5 µM Olaparib 
or 10 µM AZD2461 for 24 h, 
were irradiated or not with a 
single dose of 4 Gy. Expression 
and localization of γH2AX and 
RAD51 proteins were evaluated 
at 4 h after IR by immunofluo-
rescence experiments. c RH30 
and RD cells, pretreated or not 
with 1.5 and 5 µM Olaparib or 
5 and 10 µM AZD2461, were 
lysed for total protein extraction 
at 24 h after 4 Gy irradiation. 
Western blots showing the 
expression levels of γH2AX 
protein. Tubulin expression was 
used as internal control. Repre-
sentative blots of two independ-
ent experiments
a
b
c
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Finally, the increased expression of miR-124-3p in Olaparib- 
or AZD2461-treated RMS cells suggests that the modulation 
of this miRNA is involved in the complex molecular mecha-
nisms underlying the PARPi-mediated cytotoxicity. Inter-
estingly, low expression of miR-124-3p has been observed 
in different types of human cancers, including RMS (deep 
sequencing data reported in Megiorni et al. 2014), and the 
restoration of miR-124-3p levels is able to decrease cell sur-
vival by promoting apoptosis (Wang et al. 2016; Ma et al. 
2018; Zhang et al. 2018). The molecular mechanisms and 
pathways related to the functions of miR-124-3p in RMS 
models will be further investigated.
Effects on cell proliferation, apoptosis and DNA dam-
age were more pronounced by using higher concentrations 
of both drugs, i.e., 5 µM Olaparib and 10 µM AZD2461, 
and mainly in RH30 cells. Since BRCA1/BRCA2 mutations 
have not been found in RMS tumours (Mendes-Pereira et al. 
2009), the presence of genetic/epigenetic alterations in other 
DNA repair machinery components or related factors can-
not be excluded. To this regard, the expression of PTEN 
gene, which encodes for a protein involved in DNA DSB 
repair, is commonly suppressed in both ARMS and ERMS 
tumours (Zhu et al. 2016). The importance of PTEN defi-
ciency in the synthetic lethality driven by PARP inhibitors 
has been described in several cancers (Mendes-Pereira et al. 
2009; Dedes et al. 2010; McEllin et al. 2010; He et al. 2015). 
Therefore, the higher sensitivity to Olaparib or AZD2461 
observed in RH30 cells compared to RD cells might par-
tially be explained by the more pronounced down-regulation 
of PTEN levels in the alveolar compared to the embryonal 
cell line (our preliminary data not shown), this underlying 
the usefulness of PARPi treatment in tumours with deregu-
lated HR-linked proteins, such as PTEN, independently to 
the BRCA1/2 status alone. A different possible mechanism 
underlying the more conspicuous PARPi-mediated effects 
in ARMS cells might be related to the high levels of MYCN 
protein detectable in RH30 but not in RD cells (our pre-
liminary data not shown). These findings are consistent with 
previous studies in neuroblastoma (NB) tumours, showing 
that PARPi lead to DNA damage and cell death more effec-
tively in MYCN-amplified than in MYCN-not-amplified 
NB cell lines (Bridges et al. 2014; Verhagen et al. 2015). 
MYCN gene has been demonstrated to sustain DNA dam-
age by delaying the resolution of DNA lesions (Venere et al. 
2014), which if not properly repaired can lead to cellular 
death, this establishing a mechanistic link between MYCN 
overexpression and sensitivity to PARP inhibition.
Notably, the present study supports the possibility to 
combine PARPi with standard treatments, in particular with 
radiotherapy, in patients with RMS. Since ionising radiations 
induce DNA breaks that require PARP activity for proper 
DSB repair, PARP inhibition provides an effective tool to 
make cancer cells more radiosensitive. Previously, in vitro 
and in vivo studies have reported that a series of PARPi 
is able to radiosensitise different tumour models, including 
breast cancer, glioblastoma, neuroblastoma and lung cancer 
(Mueller et al. 2013; Bridges et al. 2014; Venere et al. 2014; 
Verhagen et al. 2015). In the present study, the synergistic 
antitumour activity of the combined treatment of PARPi and 
IR was demonstrated by the evidence that the exposure to 
Olaparib or AZD2461 radiosensitises RMS cells by amplify-
ing the quantity and the duration of DNA damage induced by 
IR. The susceptibility of tumour cells to ionising radiations 
was synergistically enhanced through the increased accu-
mulation of chromatid-type breaks, the prolonged activation 
of the G2/M checkpoint and the reduction of clonogenic 
potential in both RH30 and RD cell lines. Cell cycle regula-
tion has been reported as an important biological mechanism 
affecting radiosensitivity, with cells being most sensitive to 
radiation during the G2/M phase (Pawlik and Keyomarsi 
2004). Likewise, different drugs have been shown to pro-
mote sensitivity to radiations by inducing cells to accumu-
late in this phase (Pawlik and Keyomarsi 2004; Duangmano 
et al. 2012). Our in vitro experiments demonstrated that 
Olaparib or AZD2461 plus radiations significantly increase 
γH2AX and RAD51 expression and nuclear accumulation, 
this further confirming that the combined treatment has a 
higher sensitizing activity compared to either treatment 
modality. The increase of γH2AX and RAD51 foci is sug-
gestive of the presence of stalled fork recovery sites and 
endogenous replication stress, both signs of the attempt by 
tumour cells to repair DNA lesions (Costanzo 2011; He et al. 
2015). RAD51 upregulation contributes to G2 phase arrest 
in order to help the HR systems in fixing DNA damage, 
but an excess of RAD51 nuclear foci is thought to promote 
genomic instability for inappropriate recombination events, 
including translocations and other rearrangements, this in 
turn having deleterious effects on cell survival. Indeed, the 
sustained overexpression of RAD51 nuclear signals has 
been associated with a reduced cell growth and apoptosis, 
as observed in Drosophila as well as in human cell lines 
(Flygare et al. 2001; Yoo and McKee 2004; Klein 2008), 
which confirms that a balanced interaction between RAD51 
and other HR factors is needed to properly repair DNA.
A further interesting finding that emerges from our data 
is that low concentrations of either PARPi (1.5 µM Olaparib 
or 5 µM AZD2461) are adequate to increase substantially the 
efficacy of the ionising radiations in both RH30 and RD cell 
lines, this having potentially important clinical implications, 
since a significant level of tumour cell radiotoxicity can be 
achieved by more tolerable concentrations of PARPi and 
IR in combination. However, further studies will be needed 
to evaluate the antitumour activity and possible toxicity of 
Olaparib and AZD2461 as single agents and in combination 
with ionising radiations in RMS xenografts.
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In conclusion, the present findings demonstrate that 
PARPi may represent a promising therapeutic approach in 
RMS treatment. Furthermore, PARPi-increased sensitivity 
to radiations may be associated with a significant therapeu-
tic benefit by inhibiting tumour growth and survival and 
by counteracting the development of radioresistance, this 
potentially improving clinical outcome.
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